Stock Market News
Hikma downgraded by Jefferies on turnaround challenges
Hikma Pharmaceuticals is likely to disappoint with its outlook for the coming year, Jefferies analysts feared, downgrading the drugmaker to 'underperform'.
Jefferies, which cut the target price to 895p from 1,074p as it moved the stock off its former 'hold' rating, cut its forecasts for 2018 earnings per share by another 7% as it takes into account the recent trends and a more cautious sum-of-the-part valuation.
Analysts anticipate some write-downs on the Roxane business as it enters another "transitory year", with the company having already stated that it anticipates "low double-digit" price erosion in 2018 and with management likely to find it hard to take out more costs.
Looking at other parts of the business, competition for Hikma's Glycopyrrolate injectable has already got tougher, meaning margins are going to fall to around 32% from 33% previously.
The branded drug outlook is "likely to be sanguine", with management having previously placed the emphasis on cashflow rather than growth as hospitals have been slowing purchases and volatile FX has impacted reported growth.
"We believe the market continues to be too bullish for this segment."
The US generics is "not be the free option some might suspect", either, with Jefferies believing it will be "some time" until Hikma's business can command a sales multiple in line with the sector.
"We believe the market is likely to focus on profitability and to potentially change our stance we look to 1) new launches and positive momentum; 2) materially improving profitability; and 3) visibility on Gx Advair."
In all, while acquisition are possible, the analysts "would prefer to see the company execute on its current turnaround plan
where we see sizeable challenges".
Jefferies, which cut the target price to 895p from 1,074p as it moved the stock off its former 'hold' rating, cut its forecasts for 2018 earnings per share by another 7% as it takes into account the recent trends and a more cautious sum-of-the-part valuation.
Analysts anticipate some write-downs on the Roxane business as it enters another "transitory year", with the company having already stated that it anticipates "low double-digit" price erosion in 2018 and with management likely to find it hard to take out more costs.
Looking at other parts of the business, competition for Hikma's Glycopyrrolate injectable has already got tougher, meaning margins are going to fall to around 32% from 33% previously.
The branded drug outlook is "likely to be sanguine", with management having previously placed the emphasis on cashflow rather than growth as hospitals have been slowing purchases and volatile FX has impacted reported growth.
"We believe the market continues to be too bullish for this segment."
The US generics is "not be the free option some might suspect", either, with Jefferies believing it will be "some time" until Hikma's business can command a sales multiple in line with the sector.
"We believe the market is likely to focus on profitability and to potentially change our stance we look to 1) new launches and positive momentum; 2) materially improving profitability; and 3) visibility on Gx Advair."
In all, while acquisition are possible, the analysts "would prefer to see the company execute on its current turnaround plan
where we see sizeable challenges".
Related share prices |
---|
Hikma Pharmaceuticals (HIK) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price